New York Times Earnings Due Before the Bell: Can 15% Growth Keep the Subscription Machine Running?

Q2 expectations center on steadiness, not a turnaround

Investors are not looking for a rescue story. They are testing whether The New York Times Company can keep its usual discipline intact. Results are due before the market opens on Aug. 5, with consensus set at $748 million in Q2 revenue and 15.5% EPS growth. For a mature media business, that is a high bar. The central question is not collapse; it is whether any small wobble shows up in the numbers.

Subscription growth still drives the thesis

The market is still focused on whether The Times can keep compounding through subscriptions, bundles, and pricing power. That makes sense: the company has built its strategy around direct reader relationships across News, Games, Cooking, The Athletic, Audio, Wirecutter, and related products, and management has pointed to 10-12% total subscription revenue growth for the quarter. The last reported quarter also reinforced that thesis, with total subscription revenues rising 11.3% year over year.

Ad revenue is the second part of the story. The company's recent growth narrative has depended on subscriptions and digital ads supporting each other, so investors will want evidence that advertiser demand is still holding up. A strong quarter would extend confidence in the bundle and pricing actions. A weaker quarter would not break the business, but it could slow the market's willingness to keep rewarding the model.

A repeat of Q1 would matter

The prior quarter set a high standard. In Q1, The Times beat EPS expectations by 24.5%. Matching that kind of outperformance again would be difficult, but even a solid pass against the Q2 bar would reinforce the idea that execution remains tight.

This is why the print debate matters less than it once did. Yes, print can still drag and ad demand can cool. But the current conversation still assumes The Times is executing a proven model rather than reinventing one. If subscription growth stays healthy and the company meets expectations, the market is likely to keep treating The Times as a steady compounder rather than a story in search of proof.